Hyperthermic Intrathoracic Chemotherapy. A new weapon has been deployed in Portugal

Authors

  • Catarina Barata Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental
  • Ricardo Ferreira Serviço de Cirurgia Cardiotorácica, Centro Hospitalar Universitário de Lisboa Norte, Lisboa
  • Beatriz Draiblate Serviço de Cirurgia Cardiotorácica, Centro Hospitalar Universitário de Lisboa Norte, Lisboa
  • Filipe Pereira Serviço de Cirurgia Cardiotorácica, Centro Hospitalar Universitário de Lisboa Norte, Lisboa
  • Eva Brysch Serviço de Pneumologia, Centro Hospitalar de Lisboa Ocidental, Lisboa
  • Ângelo Nobre Serviço de Cirurgia Cardiotorácica, Centro Hospitalar Universitário de Lisboa Norte, Lisboa

Abstract

Thymoma is a relatively rare tumour, being, nonetheless, the most frequent neoplasm of the anterior mediastinum. Radical surgery is the gold-standard in every stage, with a considerable recurrence rate in locally advanced tumours. Complete resection in recurrences occurs only in a few cases. A new therapeutic strategy has emerged: the Hyperthermic Intrathoracic Chemotherapy (HITHOC), a high concentrated dose of chemotherapy applied locally, that has been used in addition to radical surgery to improve local control of pleural metastasis and other pleural tumours. We report a case of a 42-year-old woman diagnosed with Masaoka stage III thymoma, who underwent radical surgery, and later had a recurrence presenting with pleural metastasis. The patient underwent surgical resection followed by HITHOC, with success. HITHOC is proven to be safe and effective, but has not yet been widely used. To our knowledge, this was the first time that HITHOC has been implemented in Portugal.

Downloads

Download data is not yet available.

References

Rajan A, Giaccone G: Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol. 2008, 9:277-287. 10.1007/s11864-009-0083-7

Chiappetta M, Grossi U, Sperduti I, Margaritora S, Marulli Giuseppe, Fiorelli A, et al.: Which is the best treatment in recurrent thymoma? A systematic review and meta-analysis. Cancers (Basel). 2021, 13(7):1559. 10.3390/cancers13071559

Patel MD, Damodaran D, Rangole A, Shaikh S, Shah K, Bagwade R, et al: Hyperthermic intrathoracic chemotherapy (HITHOC) for pleural malignancies-experience from indian centers. Indian J Surg Oncol. 2019, 10:91-98. 10.1007/s13193-018- 0859-y

Aprile V, Bacchin D, Korasidis S, Ricciardi R, Petrini I, Ambrogi MC, et al.: Hypertermic intrathoracic chemotherapy (HITHOC) for thymoma: a narrative review on indications and results. Ann Transl Med. 2021, 9:957. 10.21037/atm-20-6704

Ambrogi MC, Korasidis S, Lucchi M, Fanucchi O, Giarratana S, Melfi F, et al.: Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy†. Eur J Cardiothorac Surg. 2016, 49:321-326. 10.1093/ejcts/ezv039

Zhou H, Wu W, Tang X, Zhou J, Shen Y: Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis. Medicine (Baltimore). 2017, 96:5532. 10.1097/MD.0000000000005532

Markowiak T, Larisch C, Hofmann HS, Ried M: Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies. Ann Transl Med. 2021, 9:955. 10.21037/atm-20-544

Published

2024-06-26

How to Cite

Barata, C., Ferreira, R., Draiblate, B., Pereira, F., Brysch, E., & Nobre, Ângelo. (2024). Hyperthermic Intrathoracic Chemotherapy. A new weapon has been deployed in Portugal. Portuguese Journal of Oncology, 7(1-2), 35–38. Retrieved from https://rponcologia.com/index.php/rpo/article/view/68